Erratum: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer (PLoS ONE (2013) 8:3 (E54014) DOI: 10.1371/journal.pone.0054014);Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Shah, Manish A ^a   Wainberg, Zev A ^b   Catenacci, Daniel V T ^c   Hochster, Howard S ^d   Ford, James ^e   Kunz, Pamela ^e   Lee, Fa Chyi ^f   Kallender, Howard ^g   Cecchi, Fabiola ^h   Rabe, Daniel C ^h   Keer, Harold ⁱ   Martin, Anne Marie ^g   Liu, Yuan ^g   Gagnon, Robert ^g   Bonate, Peter ^g   Liu, Li ^g   Gilmer, Tona ^g   Bottaro, Donald P ^h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d YALE UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g GLAXOSMITHKLINE   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORETINIB; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CONTROL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPHONIA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RETROPERITONEAL CANCER; SIDE EFFECT; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME; VOMITING;

EID: 84875035582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0261994     Document Type: Erratum

References (36)

1. World Health Organization. Global cancer rates could increase by 50% to 15 million by 2020. Available from: http://www.who.int/mediacentre/news/releases/2003/pr27/en/ Accessed 15 December 2012.
2. Kamangar F, Dores GM, Anderson WF, (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
4. Power DG, Kelsen DP, Shah MA, (2010) Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 36: 384-392.
5. Sastre J, Garcia-Saenz JA, Diaz-Rubio E, (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12: 204-13.
6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
7. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, et al. (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 101: 4477-82.
8. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, et al. (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25: 1517-1524.
9. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, et al. (1998) Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55: 475-481.
10. Tsujimoto H, Sugihara H, Hagiwara A, Hattori T, (1997) Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 431: 383-9.
11. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, et al. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232.
12. Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P, (1998) Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer 23: 307-316.
13. Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, et al. (1999) Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 24: 299-305.
14. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, et al. (2011) RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 12: 9-46.
15. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, et al. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103: 2316-2321.
16. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, et al. (2000) A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 4947-4953.
17. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS, (2001) Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 40: 638-643.
18. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, et al. (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63: 286-296.
19. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
20. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, et al. (2009) Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 69: 8009-8016.
21. Liu L, Greger J, Shi H, Liu Y, Greshock J, et al. (2009) Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69: 6871-6878.
22. Lui L, (2010) Foretinib: a multikinase AXL/MET inhibitor. J Thoracic Oncol 5 (Suppl 1; abstr 201N) (): S20.
23. Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, et al. (2010) A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16: 3507-3516.
24. LoRusso PM, Eder JP, Sherman L, McCallum S, Liu Y, et al. (2009) Abstract A8: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors. Mol Cancer Ther 8 (Suppl 1) () doi:10.1158/1535-7163.TARG-09-A8.
25. Choueiri TK, Vaishampayan UN, Rosenberg JE, Logan TF, Harzstark AL, et al. (2012) A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. J Clin Oncol 30 (suppl 5; abstr 355) ().
26. Srinivasan R, Bottaro D, Choueiri TK, Vaishampayan UN, Rosenberg JE, et al. (2012) Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). J Clin Oncol 30 (suppl 5; abstr 372) ().
27. Yau T, Yen C-J, Chen P-J, Chau Y, Lencioni R, et al. (2011) A Phase I/II Study Of Foretinib, An Oral Multikinase Inhibitor Targeting MET, RON, AXL, TIE-2 AND VEGFR In Advanced Hepatocellular Carcinoma (HCC). J Hepatol 54: S268, abstr 665.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
29. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, et al. (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20: 1021-1027.
30. Srinivasan R, Choueiri TK, Vaishampayan UN, Rosenberg JE, Stein MN, et al. (2008) A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 26 115S (May 20 Supplement) (): abstr 5103.
31. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, et al. (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5: 32.
32. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, et al. (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529.
33. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS, (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104: 17069-17074.
34. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, et al. (2008) HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7: 3499-3508.
35. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937.
36. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, et al. (2010) MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70: 7580-7590.